Date: 09 Jul 2013

Radiosurgery for Intramedullary Spinal Cord Tumors

* Final gross prices may vary according to local VAT.

Get Access


Intrinsic intramedullary spinal cord tumors (ISCTs) account for 8–10 % of all primary spinal cord tumors, while intramedullary spinal cord metastases (ISCMs) account for less than 5 % of all spinal tumors. While the overall survival of patients with primary ISCTs varies greatly with histology, ISCMs maintain a poor prognosis with a median overall survival of 4 months following diagnosis. Standard of care for both primary ISCTs and ISCMs often includes a combination of surgical resection, conventional external beam radiation therapy (EBRT), steroids, chemotherapy, hormonal therapy, and stereotactic radiosurgery (CyberKnife, LINAC, Gamma Knife). With greater access and application of stereotactic radiosurgery (SRS) in the treatment of ISCTs, data is beginning to accrue regarding patient outcomes. In this chapter, the authors review the present literature surrounding the safety and efficacy of SRS in the treatment of ISCTs and present a sample institutional experience of CyberKnife SRS.